ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO494

Proteinuria and Its Association With Disease Progression in IgA Nephropathy: Analysis of the UK National RaDaR IgA Nephropathy Cohort

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Pitcher, David, UK Renal Registry, Bristol, United Kingdom
  • Braddon, Fiona E. M., UK Renal Registry, Bristol, United Kingdom
  • Hendry, Bruce M., Travere Therapeutics Inc, San Diego, California, United States
  • Mercer, Alex, JAMCO Pharma Consulting, Stockholm, Sweden
  • Osmaston, Kate, UK Renal Registry, Bristol, United Kingdom
  • Saleem, Moin, University of Bristol, Bristol, United Kingdom
  • Steenkamp, Retha D., UK Renal Registry, Bristol, United Kingdom
  • Turner, A. Neil, University of Edinburgh, Edinburgh, United Kingdom
  • Wang, Kaijun, Travere Therapeutics Inc, San Diego, California, United States
  • Barratt, Jonathan, University of Leicester, Leicester, United Kingdom
  • Gale, Daniel P., Royal Free Hospital, London, United Kingdom

Primary IgA nephropathy (IgAN) is the most common form of glomerulonephritis worldwide and a major cause of renal failure. Here we investigate the relationship between proteinuria (PU) measured over follow-up (FU) and rate of renal function loss and renal survival in patients from the UK National Registry of Rare Kidney Diseases (RaDaR) IgAN Cohort. Since 2013, patients with biopsy-proven IgAN and eGFR <60 ml/min/1.73m2 or PU ≥0.5g/24h have been enrolled from 87 kidney units across the UK, with automated collection of retrospective and prospective laboratory data.


923 patients met the eligibility criteria, including diagnosis date, PU measurements in FU (within 2yr from diagnosis and ≥2 values if FU >3yr), no ESKD (CKD stage 5 or renal replacement therapy) or death within 6mo from diagnosis or prior to first PU value. Longitudinal PU, assessed as time-average protein-to-creatinine ratio (TA-PCR), and eGFR slope were calculated over the full duration of FU or until ESKD or death. For survival analyses, ESKD/death was applied, with survival time calculated from diagnosis to last FU.


Characteristics at diagnosis and clinical outcomes of the study population are summarized in Fig.1a. Increasing grades of TA-PCR were associated with more rapid decline in eGFR (ANOVA p<0.001, Fig.1c) and greater risk of ESKD/death (Log-rank p<0.001, Fig.1b; Cox regression p<0.001, Fig.1c).


Proteinuria exposure over time is significantly associated with disease progression and renal outcomes in IgAN. In particular, TA-PCR below 100 mg/mmol (~1g/24h) is very strongly associated with slower loss of renal function and lower risk of ESKD or death.


  • Commercial Support –